Table I.
Clinicopathological Characterization of the Basal Cell (BC)-high and BC-low Adenocarcinoma
| BC-low (n=46) | BC-high (n=46) | p value7 | |
|---|---|---|---|
| Age, mean ± S.D. | 65.9±12.2 | 68.5±8.9 | >0.2 |
| Gender | >0.8 | ||
| Male | 24 | 24 | |
| Female | 22 | 22 | |
| Smoking history | <0.04 | ||
| Never 1 | 14 | 6 | |
| Ever | 31 | 40 | |
| COPD co-morbidity | >0.1 | ||
| No | 40 | 34 | |
| Yes | 6 | 12 | |
| Pathological stage 2 | <0.05 | ||
| I | 36 | 27 | |
| II/III | 5/5 | 5/14 | |
| Tumor size, mean ± S.D. | 3.0±1.4 | 4.1±2.9 | <0.05 |
| Node metastasis | <0.04 | ||
| No (N0) | 37 | 28 | |
| Yes (N1/N2) | 6/3 | 8/10 | |
| Pathological grade | <0.001 | ||
| Well/Moderate | 19/19 | 1/21 | |
| Poor | 5 | 21 | |
| Lepidic pattern 3 | <0.001 | ||
| No | 17 | 39 | |
| Yes | 2/27 | 2/5 | |
| Vascular invasion | <0.004 | ||
| No | 35 | 18 | |
| Yes | 8 | 18 | |
| NKX2-1 (TTF-1) expression, mean ± S.D.4 | 1.20±0.55 | 0.63±0.48 | <0.001 |
| EGFR mutations 5 | <0.03 | ||
| Wild-type | 32 | 41 | |
| Mutant | 14 | 5 | |
| TP53 mutations | >0.2 | ||
| Wild | 38 | 33 | |
| Mutant | 8 | 13 | |
| KRAS mutations 6 | <0.04 | ||
| Wild-type | 39 | 30 | |
| Mutant | 7 | 16 |
Never smokers were defined as subjects who have never had a smoking habit.
Pathological stage was based on 6th edition TNM staging.
Lepidic pattern was formerly described as bronchioloalveolar carcinoma (BAC).
Normalized expression based on the microarray gene expression analysis as described in Methods; S.D., standard deviation
The patients with lung adenocarcinoma had epidermal growth factor receptor (EGFR) mutations such as deletion in exon 19 (n=24) and a point mutation (L858R) in exon 21 (n=14).
KRAS mutants included G12C (n=17), G12V (n=16), G12D (n=6), G12A (n=4), and G13D (n=1).
p values were calculated by Pearson’s chi -square test (for categorical variables) and Mann-Whitney test (for continuous values).